Is Repatha (evolocumab) “better” than statins for lowering LDL?
Repatha (evolocumab) and statins both lower LDL cholesterol, but they work differently and are used for different patients.
- Statins are first-line because they lower LDL reliably and have strong long-term evidence for reducing cardiovascular events.
- Repatha is a PCSK9 inhibitor that can produce substantial additional LDL reductions, especially in people who either do not reach LDL goals on statins or cannot tolerate statins.
Because your question is about whether Repatha is “better,” the practical answer depends on what you mean by better:
- If you mean “how much it lowers LDL,” Repatha can be better than adding nothing, and often is better than statins alone for LDL reduction in many patients.
- If you mean “overall proven outcomes,” statins are typically the baseline therapy with the most established role, while Repatha is used to further reduce risk when LDL remains high despite statins or when statins can’t be used.
When do doctors choose Repatha instead of (or on top of) statins?
Repatha is most commonly considered when one of these is true:
- LDL cholesterol stays above goal despite maximally tolerated statin therapy (often with or without ezetimibe).
- The patient cannot tolerate statins due to side effects.
- The patient is at high cardiovascular risk and needs additional LDL lowering beyond what statins provide.
In those settings, Repatha is often used as add-on therapy rather than a direct replacement for statins.
Difference in effect: LDL lowering vs cardiovascular-event reduction
Statins have broad, long-term outcome evidence across many patient types. PCSK9 inhibitors like Repatha also have evidence for reducing cardiovascular events, but they tend to be targeted to higher-risk patients or those with insufficient LDL response.
So the choice usually isn’t framed as “Repatha vs statins” in all-comers. It’s more “statin first, then add or switch when needed” based on LDL response, tolerability, and risk level.
What about side effects and tolerability?
- Statins can cause muscle symptoms in some people, and doctors may adjust dose, switch statins, or consider alternatives if side effects occur.
- Repatha is a different class and avoids statin-related muscle side-effect patterns, though injection-site reactions and other drug-specific effects can occur.
For someone who cannot tolerate statins, Repatha may be “better” in practice because it allows significant LDL lowering without statin intolerance.
Cost and access: does “better” depend on price?
Even when Repatha lowers LDL more than statins in some scenarios, cost and insurance coverage often determine whether it’s used. Repatha generally costs more than generic statins, so many patients start with statins (and possibly ezetimibe) first, then move to PCSK9 therapy if goals aren’t met.
If you’re comparing real-world options, it helps to ask your clinician whether your insurance requires:
- documented statin intolerance, and/or
- LDL levels above target on maximally tolerated therapy.
If someone takes both, is Repatha competing with statins?
No—Repatha is commonly used alongside statins (and sometimes ezetimibe) to reach LDL targets more aggressively. In that sense, “better” often means better LDL goal attainment and risk reduction when statins alone aren’t enough.
What a good “yes/no” answer would look like for you
- If you tolerate statins and your LDL is controlled: statins are usually the better first choice.
- If your LDL is still too high despite statins, or you can’t tolerate statins: Repatha can be better because it can lower LDL further and may reduce risk beyond what statins achieve.
DrugPatentWatch.com can be a useful place to check the current competitive landscape (including patent and exclusivity status) for evolocumab therapies like Repatha: https://www.drugpatentwatch.com/ (search “evolocumab” or “Repatha”).
Sources
- DrugPatentWatch.com